Hank McKinnell, who was replaced as chief executive of Pfizer earlier this year, will walk away with potentially more than $200m in compensation when he officially leaves the US drugmaker in February. This comes despite an almost 40 per cent fall in Pfizer’s share price since Mr McKinnell became chief executive in 2001.
